Navigation Links
For Treating Psoriatic Arthritis, Clinical Data and Thought Leaders' Opinions Indicate that AbbVie/Eisai's Humira Has the Best Clinical Profile Among Key Marketed Therapies
Date:6/3/2013

BURLINGTON, Mass., June 3, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that based on clinical data and the opinions of interviewed thought leaders, AbbVie/Eisai's Humira has the strongest clinical profile among key marketed products that treat psoriatic arthritis (PsA). None of the PsA therapies in development show advantages in efficacy over Humira, although UCB/Astellas's Cimzia has a clinical profile that is not differentiated from Humira based on thought leader opinion and clinical trial data.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to the DecisionBase 2013 report entitled Opportunity Remains for Novel Therapies That Address Rheumatologists' and Payers' Shared Views on Unmet Need in the TNF-Alpha-Inhibitor-Dominated PsA Market, while some other therapies in development hold promise, they have efficacy, safety and tolerability, and/or delivery disadvantages compared with Humira and Cimzia.

"The TNF-alpha inhibitors have set a high clinical standard that is challenging for emerging therapies to surpass," said Decision Resources Senior Analyst Bingnan Kang , Ph.D. "However, unmet needs exist for improvements in various efficacy, safety and tolerability, and delivery attributes. The PsA pipeline contains several agents with novel mechanisms of action that have the potential to fulfill some of these unmet needs."

The report also finds that physicians in the U.S. and Europe and managed care organization (MCO) pharmacy directors in the U.S. identify the need for new therapies with greater ability to halt progression of structural damage as a key unmet need. In addition, surveyed U.S. MCO pharmacy directors are particularly receptive to new PsA therapies that offer improved effect on signs and symptoms of arthritis over currently available therapies. Improvement of signs and symptoms and inhibition of progression of structural damage are two key treatment goals in the management of PsA.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
2. For Treating Clostridium difficile Infections, Surveyed Infectious Disease Specialists Agree That Effect on Recurrence Rate is One of the Drug Attributes that Most Influences Their Prescribing Decisions
3. Forum Tackles the Rising Costs, Challenges and Diminished Outcomes Associated with Treating Obese Patients for Orthopaedic Conditions
4. Treating Poison Ivy Is A Snap! New Cortizone 10 Poison Ivy Relief Pads Launch Just In Time For Summer
5. Elektas Advanced Versa HD System to Begin Treating Cancer Patients at New Swiss Radiotherapy Clinic
6. Professional Therapy Associates Study Supports Findings: Physical Therapy Beneficial in Treating Office Workers with Lower Back Pain
7. Abattis Participates In Project On A Whole Plant Therapeutic For Treating Malaria And Other Diseases And Reducing Drug Resistance
8. Varian Medical Systems to Showcase Advanced Technologies for Treating Cancer with Image-Guided Radiotherapy and Radiosurgery at JASTRO Meeting in Tokyo, Japan
9. The Nairobi Hospital in Kenya Commences Treating Cancer with Advanced Radiotherapy Delivery Using Varian Equipment and Software
10. The Growing Cost of Aging: Express Scripts Study Shows Medication Use for Normal Aging Conditions Overtakes Costs of Treating Most Chronic Diseases
11. Avaxia Biologics is Awarded U.S. Patent for Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... 16, 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ... today announced that executive management will participate in the ... February 22-23, 2017. Adrian Adams , Chief Executive ... 1:35 p.m. local time on Wednesday, February 22, 2017. ... the event may be accessed from the Investors section ...
(Date:2/16/2017)... REDWOOD CITY, Calif. , Feb. 16, 2017 ... ), a specialty pharmaceutical company focused on the ... treatment of moderate-to-severe acute pain, announced that ... executive officer and a member of the company,s ... Mr. Angotti brings over two decades of experience ...
(Date:2/16/2017)... 16, 2017 Research and Markets has announced ... Analysis & Trends - Function, Application, Cancer Type, Technology - Forecast ... ... Market is poised to grow at a CAGR of around 28.6% ... Some of the prominent trends that the ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... For the first time, International ... the exhibit floor for the 2017 HIMSS Conference & Exhibition at ... 2017, more than 40,000 healthcare industry professionals are expected at the conference, where ...
(Date:2/17/2017)... ... February 17, 2017 , ... Empowering each person's ... goals for each and every seminar, session and class she offers. At ... brainwave tools which help energize creativity, focus mental functions, enhance athletic focus and ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... named a finalist in the 8th Annual DecisionHealth Platinum Awards in recognition of ... Qualis Health’s work is recognized across multiple award categories, highlighting four of the ...
(Date:2/17/2017)... ... February 17, 2017 , ... Program will ... Trinity Health and the U.S. Soccer Foundation announced today that they have awarded ... Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the fundamentals of ...
(Date:2/17/2017)... ... February 17, 2017 , ... Pharmica Consulting ... on all facets of clinical trial planning and management. Pharmica discussed the importance ... more. In addition, attendees stopping by Pharmica’s booth were able to demo its ...
Breaking Medicine News(10 mins):